The benefit of a sentinel lymph node (SLN) biopsy and adjuvant therapy for patients with thick (> 4 mm) melanoma has not been well studied in the Asian population. We examined the benefit of an SLN biopsy and adjuvant therapy on prognosis in Japanese patients with thick melanoma. A review of the melanoma database collected from 26 institutions in Japan identified 291 patients with thick melanoma between 2005 and 2010. Univariate and multivariate analyses were performed to evaluate the factors predictive of the overall survival (OS) and the disease-free survival (DFS). Of the 242 patients with thick melanoma who underwent an SLN biopsy, the results for 96 (40%) were positive. On multivariate analysis, increased Breslow thickness (relative risk, 1.11; 95% confidence interval, 1.05-1.17; P = 0.0002) and SLN metastasis (2.14; 1.04-4.43; P = 0.040) were associated with a poor OS. Increased Breslow thickness (1.11; 1.04-1.18; P = 0.0018), ulceration (3.11; 1.25-7.72; P = 0.014), satellitosis (3.89; 1.62-9.31; P = 0.0023), and SLN metastasis (2.24; 1.16-4.36; P = 0.017) were associated with DFS. Adjuvant chemotherapy had no impact on either OS or DFS. Adjuvant use of a monthly dermal injection of interferon-b (IFN-b) was associated with a improvement in both OS (0.34; 0.17-0.67; P = 0.0022) and DFS (0.42;; P = 0.018). An SLN biopsy provided useful prognostic information and the adjuvant use of IFN-b improved both OS and DFS in Japanese patients with thick melanoma. These results were consistent with those of previous studies carried out on a white population. Therefore, we suggest that an SLN biopsy and adjuvant IFN should be considered for patients with thick melanoma irrespective of the Breslow thickness or ethnicity.
The benefit of a sentinel lymph node (SLN) biopsy and adjuvant therapy for patients with thick (> 4 mm) melanoma has not been well studied in the Asian population. We examined the benefit of an SLN biopsy and adjuvant therapy on prognosis in Japanese patients with thick melanoma. A review of the melanoma database collected from 26 institutions in Japan identified 291 patients with thick melanoma between 2005 and 2010. Univariate and multivariate analyses were performed to evaluate the factors predictive of the overall survival (OS) and the disease-free survival (DFS). Of the 242 patients with thick melanoma who underwent an SLN biopsy, the results for 96 (40%) were positive. On multivariate analysis, increased Breslow thickness (relative risk, 1.11; 95% confidence interval, 1.05-1.17; P = 0.0002) and SLN metastasis (2.14; 1.04-4.43; P = 0.040) were associated with a poor OS. Increased Breslow thickness (1.11; 1.04-1.18; P = 0.0018), ulceration (3.11; 1.25-7.72; P = 0.014), satellitosis (3.89; 1.62-9.31; P = 0.0023), and SLN metastasis (2.24; 1. 16-4.36 ; P = 0.017) were associated with DFS. Adjuvant chemotherapy had no impact on either OS or DFS. Adjuvant use of a monthly dermal injection of interferon-b (IFN-b) was associated with a improvement in both OS (0.34; 0.17-0.67; P = 0.0022) and DFS (0.42; 0.20-0.86; P = 0.018). An SLN biopsy provided useful prognostic information and the adjuvant use of IFN-b improved both OS and DFS in Japanese patients with thick melanoma. These results were consistent with those of previous studies carried out on a white population. Therefore, we suggest that an SLN biopsy and adjuvant IFN should be considered for patients with thick melanoma irrespective of the Breslow thickness or ethnicity. 
Introduction
Fifteen to 20 percent of patients with clinically localized melanoma of intermediate thickness (1-4 mm Breslow thickness) have occult lymph node metastasis. Before Morton et al. [1] proposed the sentinel lymph node (SLN) concept, immediate elective lymphadenectomy was advocated to improve tumor staging and possibly survival [2, 3] despite the risk or surgery-related complications. For patients with intermediate-thickness melanoma, an SLN biopsy has become the standard method for determining the pathologic status of the regional nodal basin [4] .
However, controversy remains as to whether an SLN biopsy has any merit for patients with thin melanoma (r 1 mm Breslow thickness) or thick melanoma (> 4 mm Breslow thickness). Because the risk of nodal metastasis for patients with thin melanoma is as low as 5% [4] , patients without risk factors such as ulceration or mitotic activity are not likely to benefit from an SLN biopsy. Therefore, discussion has centered on the identification of a subset of these patients who may still benefit from an SLN biopsy [5, 6] .
The risk of thick melanoma nodal metastasis is reported to be almost 40% [7] [8] [9] . Moreover, this patient population is at a high risk for systemic occult disease [10] . Given these facts, the benefit of an SLN biopsy in patients with thick melanoma is still controversial [8] . However, some reports that have examined the role of an SLN biopsy in thick melanoma have shown that the SLN status provided important prognostic information [11, 12] . According to these studies, patients with no evidence of a tumor in the SLN had significantly better disease-free survival (DFS) as well as overall survival (OS) than SLNpositive patients.
Previous large-scale population studies have all been carried out in western countries. The clinical evidence for Asian patients, especially from large-scale studies, is limited, and little is known about melanoma in Asian populations. This is because melanoma is relatively rare in non-white populations. According to the Surveillance, Epidemiology, and End Results (SEER) data from the USA, the incidence of melanoma in Asians is about 1 in 100 000 individuals as compared with that in the white population of 20 in 100 000 individuals (SEER data, 2004 (SEER data, -2008 ; http://seer.cancer. gov/statfacts/html/melan.html#incidence-mortality). Moreover, the clinical characteristics such as the pathology, anatomical origin, and patient's prognosis differ significantly among different ethnic groups [13] . Therefore, whether previous study results can be applied to Asian populations needs to be confirmed.
The aim of this study was to determine the effect of an SLN biopsy and adjuvant therapy on Japanese patients with thick melanoma.
Materials and methods
The Japanese Melanoma Study is a prospective cohort study involving 26 centers in Japan that started in 2005. All patients diagnosed with melanoma are registered with this database; so far, 2126 patients have been registered. We extracted data from this database that fulfilled the following criteria: pathologically confirmed primary cutaneous melanoma, Breslow thickness more than 4 mm, clinically lymph node negative, without elective lymph node dissection, without distant metastasis, and records with survival time. Because DAVFeron [dacarbazine, nimustine hydrochloride, vincristine, interferon-b (IFN-b)] therapy is the only adjuvant chemotherapy method recommended in the General Rules for Clinical and Pathological Studies on Malignant Neoplasms of the Skin [14] , we excluded data from patients who had received other adjuvant chemotherapy to standardize the therapeutic methods. Finally, 291 consecutive cases were eligible for this analysis.
An SLN biopsy with a peritumoral intradermal injection of technetium-99m sulfur colloid or phytate colloid and intradermal patent blue dye was performed. The SLNs were serial sectioned with hematoxylin-eosin staining and immunohistochemistry for S-100 and HMB-45 as recommended [14] in most cases. Survival information was obtained from the registered database.
This study was approved by the institutional review board of the University of Tsukuba.
Statistical methods
The associations between groups were tested using the w 2 -test and the t-test for categorical and continuous characteristics, respectively. The OS and DFS were calculated for each patient beginning from the date of the primary surgery. For OS, patients confirmed to be alive were censored using their last contact date. For DFS, patients confirmed to be alive without locoregional relapse or distant metastasis were censored using their last contact date. The estimated OS and DFS were calculated using the Kaplan-Meier method. The Cox proportional hazard model was used to estimate the bivariate association between each end point and the available patient/tumor characteristics and the type of adjuvant therapy. The best multivariate model was defined as the model that resulted from the application of a stepwise regression (forward selection) algorithm that automatically eliminated the variables with P values > 0.05 until only significant characteristics remained. Significance for all statistical tests was defined as a P value > 0.05. All analyses were performed using commercially available software (Stat Flex version 6.0; Artech, Osaka, Japan).
Results

Patient characteristics
The patient characteristics of this study are listed in Table 1 . The mean age of the patients was 69 years. The median Breslow thickness was 5.9 mm, with a range of 4-25 mm. The primary tumor distribution occurred most commonly in the foot and was relatively well distributed in the head and neck, trunk, and hand. Ulceration was present in 63% of the patients, regression in 4%, and satellitosis in 8%. An SLN biopsy was performed in 241 patients (83%). Adjuvant chemotherapy and IFN-b protocol-2 were performed in approximately half of the population (48 and 44%, respectively) and the IFN-b protocol-1 was performed in just over one quarter of the population (28%).
Sentinel lymph node status
Of the 291 patients, 50 (17%) did not undergo an SLN biopsy. The reason for this is unclear, but given the higher average age in this group than in the group that did undergo the biopsy (76.8 vs. 63.8 years; t-test, P < 0.00001), the patients' elderly age and comorbidities might have been determining factors. Among patients who did undergo an SLN biopsy, the median number of harvested SLNs per case was 2 (range, 1-10). In 12 patients, an SLN biopsy was attempted, but failed.
The SLN was positive in 96 patients (40%). The factors associated with a positive SLN are listed in Table 2 . Age was not associated with SLN positivity. There were a higher number of women in the SLN-positive group than in the SLN-negative group (P = 0.055). The proportion of the acral lentiginous melanoma (ALM) histologic subtype was lower in the SLN-positive group than that in the SLNnegative group (P = 0.011). Breslow thickness is known to be strongly predictive of SLN positivity, and the incidence of SLN positivity increases significantly with increasing thickness (P =0.03). Other factors such as ulceration, regression, and satellitosis were not correlated with SLN positivity.
Of the 96 patients found to be SLN positive, 79 underwent complete lymph node dissection (CLND). Of these patients, 23 (29%) had non-SLN metastasis. Although we are not aware of the precise reasons why the SLN-positive patients did not receive CLND, the older age of these patients (mean, 73.0 years) as compared with the patients who did receive CLND (mean, 59.4 years) might have been an important factor. The SLN status showed no significant correlation with treatment choice.
Survival
The mean follow-up for the entire cohort was 24.5 months. During the follow-up, 83 patients (29%) developed recurrent melanoma and 46 (16%) died of the disseminated disease. An SLN biopsy conferred no survival benefit (Fig. 1) .
The association between prognostic factors and both OS and DFS was studied in patients with thick melanomas who had undergone a successful SLN biopsy. SLN-positive patients had a shorter OS than SLN-negative patients (Fig. 2) . The 3-year OS for SLN-positive patients was 65% as compared with 87% for SLN-negative patients (log-rank method, P < 0.005). Univariate analysis showed the following five factors as being significantly predictive of OS (Table 3) Next, we examined the effect of these factors on DFS. SLN-positive patients had shorter DFS than SLN-negative patients (Fig. 3) . The 3-year DFS for SLN-positive patients was 52% compared with 76% for SLN-negative patients (log-rank method, P < 0.005). As shown in Table 4 , univariate analysis showed that DFS was significantly associated with the following four factors: increasing Breslow thickness (relative risk, 1.14; 95% confidence interval, 1.04-1.21; P < 0.00001), tumor-positive SLN Kaplan-Meier overall survival analysis for patients with thick primary melanoma who underwent a sentinel lymph node biopsy or nodal observations. SLN, sentinel lymph node.
(2.58; 1.31-5.10; P = 0.0063), presence of satellitosis (2.90; 1.32-6.37; P = 0.0080), and adjuvant IFN-b (0.40; 0.20-0.79; P = 0.0081). Multivariate analysis showed that the presence of ulceration (3.11; 1.25-7.72; P = 0.014) was also significantly associated with DFS in addition to the following four factors (Table 4) 
Discussion
In the current analysis of 291 Japanese patients diagnosed with thick melanoma, we found that the histologic subtype of ALM was quite common, up to 50%. This observation is consistent with previous data obtained from other Asian populations [15, 16] . Some reports have suggested that patients with the histologic subtype of ALM have shorter survival than patients with other subtypes [15, 17] . Therefore, it was necessary to confirm whether the evidence obtained from studies using white populations can be directly applied to patients of Asian populations.
The median tumor thickness in our study population was 5.9 mm, indicating a locally advanced tumor and a high risk of systemic disease [18] . Although the benefit of an SLN biopsy for thick melanoma is still controversial [19] , recent studies on white patients with thick melanoma have shown that the SLN status was an independent prognostic factor for both OS and DFS [11, 12] . In the present study, 241 patients underwent an SLN biopsy, but the remaining 50 patients did not. We could not find any difference in survival between the patients who underwent an SLN biopsy and those who underwent a nodal examination (Fig. 1 ).
We found that almost 42% (96 of 229) of the patients in this population had SLN metastasis, which is a rate similar to that of previous reports [7, 11, 12, 20] . As shown in Table 2 , SLN-positive patients had a lower rate of the ALM subtype and increased Breslow thickness. Other factors including ulceration were not statistically correlated with the results of an SLN biopsy. In this analysis, SLNnegative patients had a significantly better OS as well as DFS (log-rank method, P < 0.005). The multivariate analysis showed that increased Breslow thickness and SLN status affected OS. Previous reports have concluded that the OS of thick melanoma was affected by the following factors: increased Breslow thickness [11, 12] , ulceration [7, 12] , and SLN status [7, 11, 12] . It is noteworthy that SLN status was found to be an independent prognostic factor of OS in all of the studies including ours, which focused on thick melanomas [7, 11, 12] . Our results confirmed that the SLN status is also an independent prognostic factor for thick melanoma in the Japanese population.
In the present study, multivariate analysis showed that increased Breslow thickness, ulceration, satellitosis, and SLN status affect DFS. Others have also reported the impact of increased Breslow thickness [12, 21] , ulceration [7, 9, 11] , and SLN status [7, 9, 11, 12, 21] on DFS. SLN status was identified as an independent prognostic factor of DFS as well as for OS. Our study also showed satellitosis to be an independent prognostic factor for DFS; however, recent studies [7, 9, 12, 21] have failed to show a significant association. Gajdos et al. [11] showed the significance of satellitosis by univariate analysis, but not by multivariate analysis. Our results support the inclusion of satellitosis in the current American Joint Committee of Cancer (AJCC) staging system.
To improve the outcome data and to reduce the risk of recurrence for thick melanoma, several treatments have been performed, including adjuvant chemotherapy using dacarbazine (DTIC) or nonspecific immune adjuvants. However, such attempts have failed to improve survival [22] . To date, the only Federal Drug Administration-approved adjuvant therapy for thick melanoma and/or regional lymph node metastasis is high-dose IFN-a. However, since Yamamoto and Ishihara [23] showed that a combination chemotherapy regimen using DTIC, nimustine hydrochloride, vincristine, and IFN-b (DAVFeron) improved survival in high-risk melanoma, this chemotherapy regimen has become widely accepted for the management of AJCC stage 2 and stage 3 melanomas in Japan. Adjuvant IFN-b is also accepted. However, no randomized-controlled study has been carried out to prove the impact of DAVFeron and adjuvant IFN-b on DFS or OS. Moreover, several cases of DAV therapy-related myelodysplastic syndrome have been reported [24] . Although ours is a prospective cohort study, we concluded that chemotherapy using the DAV regimen had no effect on DFS and OS. However, the IFN-b protocol-2 (3 million units dermal injection of IFN-b once a month continued for at least 1 year) exerted a significant survival benefit on both DFS and OS. This result is in agreement with the study of Garbe et al. [25] , who showed that a subcutaneous injection of 3 million units IFN-a significantly improved both the DFS and the OS of AJCC stage 3 melanoma.
Conclusion
An SLN biopsy provides important prognostic information in thick melanoma, and low-dose IFN-b improves both DFS and OS. These observations are in agreement with previous studies on white populations, with no ethnic differences observed. We strongly suggest the routine use of an SLN biopsy and low-dose IFN therapy in patients with thick melanoma because both procedures can be performed safely. Further studies evaluating their influence are required.
